Gold prices steady ahead of Fed decision, Trump’s tariff deadline
OCEANSIDE, Calif. - AOTI, Inc. (AIM:AOTI) announced Monday it has been granted a provider ID in California’s Medicaid program, allowing the company to seek insurance coverage for its TWO2® therapy in the state.
California represents the largest Medicaid market in the United States with 14.7 million people, or 38% of the state’s population, enrolled in Medi-Cal. This marks the third state this year where AOTI has secured a provider ID, aligning with the company’s stated goal of adding two to three states annually.
The California approval follows AOTI’s strategy to expand access to its wound care technology, which is designed to treat chronic wounds and prevent amputations. The company indicated this development will support its growth plans for late 2026.
"Securing market access in California is a major achievement and will allow us to begin to deliver the clinical and cost saving benefits of our TWO2® therapy to patients, providers and payors in the largest Medicaid market in the US," said Dr. Mike Griffiths, Chief Executive Officer of AOTI, in the press release.
Medicaid currently provides healthcare coverage to approximately 83 million low-income Americans, representing one-quarter of the U.S. population and one-fifth of all healthcare spending in the country.
AOTI’s TWO2® therapy has shown in clinical studies to reduce recurrence of Diabetic Foot Ulcers, with the company reporting an 88% reduction in hospitalizations and 71% reduction in amputations over a 12-month period.
The medical technology company, headquartered in Oceanside, California with operations in Galway, Ireland, is also pursuing coverage approval from the Centers for Medicare & Medicaid Services (CMS).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.